Moderna Inc. (MRNA) stock plummeted 5.01% in the intraday trading session on Tuesday, as the biotechnology company announced a significant downward revision to its 2025 sales guidance, citing challenges with its product pipeline and increasing competition.
The company now expects total revenues in the range of $1.5 billion to $2.5 billion for 2025, marking a substantial reduction of $1 billion from its previous guidance. This revised forecast fell well below Wall Street analysts' expectations, which had anticipated revenues of around $2.94 billion for the year.
Moderna attributed the guidance cut to several factors, including lower-than-expected sales of its COVID-19 vaccine and the anticipated launch of its next-generation vaccine candidate, mRNA-1283, which is awaiting regulatory approval. Additionally, the company faced a setback with its cytomegalovirus (CMV) vaccine candidate, as an independent data monitoring committee recommended continuing the late-stage CMVictory study, indicating that the vaccine did not meet the criteria for early efficacy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.